Wednesday, November 29, 2023
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

More Weight Loss With Mounjaro Than Ozempic: Data Analysis

November 28, 2023
in Health News
Share on FacebookShare on Twitter


(Reuters) – Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly’s Mounjaro than those taking Novo Nordisk’s popular rival weight loss drug, according to an analysis of health records and other data.

Within one year of starting treatment, 42.3% of those taking tirzepatide – the active ingredient in Mounjaro and Zepbound – had lost at least 15% of their weight, compared with 19.3% among patients taking semaglutide – the main ingredient in Wegovy and Ozempic, the study published on medRxiv in advance of peer review found.

After accounting for individual risk factors, patients taking Mounjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than three times as likely to lose at least 15%, compared to patients taking Ozempic, the report said.

In the absence of head-to-head randomized controlled trials comparing the two drugs, researchers used electronic health records and pharmacy dispensing data to analyze weight loss trajectories in 9,193 patients receiving Mounjaro and the same number of closely matched patients receiving Ozempic. The average participant weighed 242 pounds (110 kg), and about half had type 2 diabetes.

After 3 months of treatment, patients on Mounjaro had lost an average of 2.3% more body weight than those taking Ozempic, the study also found. By 6 months, the difference had widened to 4.3%, and by 12 months, the Mounjaro group had lost an average of 7.2% more weight.

Rates of gastrointestinal adverse events were similar between groups, the researchers said.

The researchers note that Ozempic and Mounjaro are both intended for use by people with type 2 diabetes, but half of the study participants were using the drugs for weight loss only, which may have impacted the results.

Novo Nordisk in an emailed statement said, “The doses of semaglutide evaluated in this analysis have not been investigated for chronic weight management, and there are no head-to-head trials that have (been) reported which evaluate Wegovy and tirzepatide.”

An Eli Lilly spokesperson said the company does not promote or encourage the off-label use of any of its medicines, although its drug is now approved for weight loss.

A trial is underway comparing the weight loss formulations of the two injected medicines in patients overweight or obese but without type 2 diabetes. Those results are not expected until 2025.

Meanwhile, the Novo spokesperson pointed out that the study report notes: “This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.”

(Reporting by Nancy Lapid; editing by Bill Berkrot)



Source link : https://www.medscape.com/s/viewarticle/998824?src=rss

Author :

Publish date : 2023-11-28 14:11:48

Copyright for syndicated content belongs to the linked Source.
Previous Post

Mailing HPV Self-Sampling Kits to Patients Boosted Cervical Cancer Screening

Next Post

UK Reaches Deal With Unions Which Could End Doctor Strikes

Related Posts

Health News

Finding happiness after the Clutha helicopter crash

November 29, 2023
Health News

Cantaloupe Linked to Salmonella Outbreak That Has Sickened 99

November 29, 2023
Health News

Sir Elton John to address MPs after HIV testing trials success

November 29, 2023
Health News

Common Headaches May Be Pains in the Neck

November 29, 2023
Health News

Thalidomide: Australia gives national apology to survivors and families

November 29, 2023
Health News

Tapinarof Effective for AD in Patients as Young as 2 years

November 29, 2023
Load More

Finding happiness after the Clutha helicopter crash

November 29, 2023

Cantaloupe Linked to Salmonella Outbreak That Has Sickened 99

November 29, 2023

Sir Elton John to address MPs after HIV testing trials success

November 29, 2023

Common Headaches May Be Pains in the Neck

November 29, 2023

Thalidomide: Australia gives national apology to survivors and families

November 29, 2023

Tapinarof Effective for AD in Patients as Young as 2 years

November 29, 2023

Stephen Colbert Cancels Shows to Recover From Ruptured Appendix, What to Know

November 28, 2023

Nail Psoriasis in Black Patients Often Overlooked

November 28, 2023
Load More

Categories

Archives

November 2023
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
« Oct    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version

More Weight Loss With Mounjaro Than Ozempic: Data Analysis- & $ More Weight Loss With Mounjaro Than Ozempic: Data Analysis * More Weight Loss With Mounjaro Than Ozempic: Data Analysis | More Weight Loss With Mounjaro Than Ozempic: Data Analysis | More Weight Loss With Mounjaro Than Ozempic: Data Analysis | More Weight Loss With Mounjaro Than Ozempic: Data Analysis | More Weight Loss With Mounjaro Than Ozempic: Data Analysis | More Weight Loss With Mounjaro Than Ozempic: Data Analysis | More Weight Loss With Mounjaro Than Ozempic: Data Analysis | More Weight Loss With Mounjaro Than Ozempic: Data Analysis | | More Weight Loss With Mounjaro Than Ozempic: Data Analysis | | More Weight Loss With Mounjaro Than Ozempic: Data Analysis | | More Weight Loss With Mounjaro Than Ozempic: Data Analysis |

NEWSHEALTH : More Weight Loss With Mounjaro Than Ozempic: Data Analysis